Kaplan M, Hammerman C, Renbaum P, Klein G, Levy-Lahad E
Lancet. 2000 Aug 19;356(9230):652-3. doi: 10.1016/S0140-6736(00)02610-6.
We asked whether UDP glucuronosyltransferase (UGT) gene promoter polymorphism (Gilbert's syndrome) would increase hyperbilirubinaemia in direct Coombs' negative ABO-incompatible neonates, as seen in other combinations with this condition. 40 ABO-incompatible and 344 ABO-compatible controls had an allele frequency of 0.35 for the variant promoter gene. The incidence of hyperbilirubinaemia was significantly higher only in the former who were also homozygotes for the variant UGT promoter, compared with ABO-incompatible babies homozygous for the normal UGT promoter (43% vs 0, p=0.02), and with ABO-compatible controls of all UGT genotypes combined (relative risk 5.65, 95% CI 2.23-14.31). Gilbert's syndrome is a determining factor for neonatal hyperbilirubinaemia ABO incompatibility.
我们探讨了尿苷二磷酸葡萄糖醛酸基转移酶(UGT)基因启动子多态性(吉尔伯特综合征)是否会像在其他合并该病症的情况中那样,增加直接抗人球蛋白试验阴性的ABO血型不相容新生儿的高胆红素血症发生率。40例ABO血型不相容婴儿和344例ABO血型相容对照婴儿中,变异型启动子基因的等位基因频率为0.35。与正常UGT启动子纯合子的ABO血型不相容婴儿相比(43%对0,p = 0.02),以及与所有UGT基因型合并的ABO血型相容对照婴儿相比(相对风险5.65,95%可信区间2.23 - 14.31),仅在前一组同时也是变异型UGT启动子纯合子的婴儿中,高胆红素血症的发生率显著更高。吉尔伯特综合征是新生儿ABO血型不相容性高胆红素血症的一个决定性因素。